Literature DB >> 21603505

Pathogenesis of prostate cancer: lessons from basic research.

Vamsidhar Velcheti, Satish Karnik, Stephen F Bardot, Om Prakash.   

Abstract

In the United States, prostate cancer is the second most common cause of cancer-related deaths in men. While the importance of androgens and androgen receptors (ARs) in primary prostate cancer is well established, the role of ARs in prostate cancers that emerge despite androgen ablation therapies remains poorly understood. The aim of this article is to illustrate the fundamental biology of prostate cancer. We focus mainly on the AR because of its critical role in the progression and metastatic spread of prostate cancer. We also summarize the alternate pathways that may potentially contribute to the progression of prostate cancer. Identifying the underlying mechanisms of androgen independence is crucial in the design of appropriate therapies for hormone-refractory neoplasms.

Entities:  

Keywords:  adenocarcinoma; androgen receptor; hormone resistance; prostate; signaling pathways; testosterone

Year:  2008        PMID: 21603505      PMCID: PMC3096366     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  43 in total

Review 1.  Significance of the polyglutamine tract polymorphism in the androgen receptor.

Authors:  R Casella; M R Maduro; L I Lipshultz; D J Lamb
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

Review 2.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

3.  Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.

Authors:  K Haapala; E R Hyytinen; M Roiha; M Laurila; I Rantala; H J Helin; P A Koivisto
Journal:  Lab Invest       Date:  2001-12       Impact factor: 5.662

Review 4.  Wnt signalling and prostate cancer.

Authors:  G W Yardy; S F Brewster
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

5.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Authors:  C Palmberg; P Koivisto; L Kakkola; T L Tammela; O P Kallioniemi; T Visakorpi
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

6.  Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.

Authors:  W K Kelly; S Slovin; H I Scher
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

7.  Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Authors:  Lorella Bonaccorsi; Sara Marchiani; Monica Muratori; Gianni Forti; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-16       Impact factor: 4.553

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 9.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

Review 10.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.

Authors:  S R Denmeade; X S Lin; J T Isaacs
Journal:  Prostate       Date:  1996-04       Impact factor: 4.104

View more
  5 in total

1.  Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines.

Authors:  Canan Eroğlu; Mücahit Seçme; Gülseren Bağcı; Yavuz Dodurga
Journal:  Tumour Biol       Date:  2015-06-30

2.  The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin.

Authors:  Yavuz Dodurga; Cığır Biray Avcı; Sunde Yılmaz Susluer; N Lale Satıroğlu Tufan; Cumhur Gündüz
Journal:  Mol Biol Rep       Date:  2012-09-25       Impact factor: 2.316

3.  Enantiomerically pure β-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways.

Authors:  Mei-Ling Chan; Chia-Chun Yu; Jui-Ling Hsu; Wohn-Jenn Leu; She-Hung Chan; Lih-Ching Hsu; Shih-Ping Liu; Polina M Ivantcova; Özdemir Dogan; Stefan Bräse; Konstantin V Kudryavtsev; Jih-Hwa Guh
Journal:  Oncotarget       Date:  2017-05-20

Review 4.  Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.

Authors:  Bartosz Malinowski; Michał Wiciński; Nikola Musiała; Ilona Osowska; Mateusz Szostak
Journal:  Diagnostics (Basel)       Date:  2019-10-25

Review 5.  The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy.

Authors:  Elisabeth A Messner; Thomas M Steele; Maria Malvina Tsamouri; Nazila Hejazi; Allen C Gao; Maria Mudryj; Paramita M Ghosh
Journal:  Biomedicines       Date:  2020-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.